These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 23116602)

  • 41. ["Before and after CML": illness experiences and dimensions of chronic myeloid leukemia as a biographical disruption].
    López YA; Trad LA
    Cad Saude Publica; 2014 Oct; 30(10):2199-208. PubMed ID: 25388322
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessment of Quality of Life of Chronic Myeloid Leukemia Patients by Using the EORTC QLQ-C30.
    Uğur MC; Kutbay YB; Özer Kaya Ö; Ceylan C
    Turk J Haematol; 2017 Jun; 34(2):197-199. PubMed ID: 28044992
    [No Abstract]   [Full Text] [Related]  

  • 43. Adapting an Evidence-Based Intervention to Address Targeted Therapy-Related Fatigue in Chronic Myeloid Leukemia Patients.
    Poort H; Meade CD; Knoop H; Gielissen MFM; Pinilla-Ibarz J; Jacobsen PB
    Cancer Nurs; 2018; 41(1):E28-E37. PubMed ID: 27832018
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia.
    Williams LA; Garcia Gonzalez AG; Ault P; Mendoza TR; Sailors ML; Williams JL; Huang F; Nazha A; Kantarjian HM; Cleeland CS; Cortes JE
    Blood; 2013 Aug; 122(5):641-7. PubMed ID: 23777764
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cognitive and other predictors of change in quality of life one year after treatment for chronic myelogenous leukemia or myelodysplastic syndrome.
    Chang G; Meadows ME; Smallwood JA; Antin JH; Orav EJ
    J Neuropsychiatry Clin Neurosci; 2014; 26(3):249-57. PubMed ID: 24817387
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
    Kantarjian HM; Cortes JE; Kim DW; Khoury HJ; Brümmendorf TH; Porkka K; Martinelli G; Durrant S; Leip E; Kelly V; Turnbull K; Besson N; Gambacorti-Passerini C
    Blood; 2014 Feb; 123(9):1309-18. PubMed ID: 24345751
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
    Whiteley J; Reisman A; Shapiro M; Cortes J; Cella D
    Curr Med Res Opin; 2016 Aug; 32(8):1325-34. PubMed ID: 27045164
    [TBL] [Abstract][Full Text] [Related]  

  • 48. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.
    Efficace F; Baccarani M; Breccia M; Saussele S; Abel G; Caocci G; Guilhot F; Cocks K; Naeem A; Sprangers M; Oerlemans S; Chie W; Castagnetti F; Bombaci F; Sharf G; Cardoni A; Noens L; Pallua S; Salvucci M; Nicolatou-Galitis O; Rosti G; Mandelli F
    Qual Life Res; 2014 Apr; 23(3):825-36. PubMed ID: 24026634
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.
    Efficace F; Baccarani M; Breccia M; Cottone F; Alimena G; Deliliers GL; Baratè C; Specchia G; Di Lorenzo R; Luciano L; Turri D; Martino B; Stagno F; Dabusti M; Bergamaschi M; Leoni P; Simula MP; Levato L; Fava C; Veneri D; Sica S; Rambaldi A; Rosti G; Vignetti M; Mandelli F
    Leukemia; 2013 Jul; 27(7):1511-9. PubMed ID: 23417029
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.
    Gambacorti-Passerini C; Cortes JE; Lipton JH; Dmoszynska A; Wong RS; Rossiev V; Pavlov D; Gogat Marchant K; Duvillié L; Khattry N; Kantarjian HM; Brümmendorf TH
    Am J Hematol; 2014 Oct; 89(10):947-53. PubMed ID: 24944159
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population pharmacokinetic and pharmacodynamic analysis of bosutinib.
    Hsyu PH; Mould DR; Abbas R; Amantea M
    Drug Metab Pharmacokinet; 2014; 29(6):441-8. PubMed ID: 24919837
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.
    Brümmendorf TH; Cortes JE; de Souza CA; Guilhot F; Duvillié L; Pavlov D; Gogat K; Countouriotis AM; Gambacorti-Passerini C
    Br J Haematol; 2015 Jan; 168(1):69-81. PubMed ID: 25196702
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up.
    Gambacorti-Passerini C; Brümmendorf TH; Kim DW; Turkina AG; Masszi T; Assouline S; Durrant S; Kantarjian HM; Khoury HJ; Zaritskey A; Shen ZX; Jin J; Vellenga E; Pasquini R; Mathews V; Cervantes F; Besson N; Turnbull K; Leip E; Kelly V; Cortes JE
    Am J Hematol; 2014 Jul; 89(7):732-42. PubMed ID: 24711212
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy.
    Efficace F; Stagno F; Iurlo A; Breccia M; Cottone F; Bonifacio M; Abruzzese E; Castagnetti F; Caocci G; Crugnola M; Capodanno I; Martino B; Tiribelli M; Patriarca A; Gozzini A; Pregno P; Saussele S; Cascavilla N; Fozza C; Bergamaschi M; Binotto G; Vignetti M; Rosti G
    Leukemia; 2020 Feb; 34(2):488-498. PubMed ID: 31477798
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.
    Cortes JE; Khoury HJ; Kantarjian HM; Lipton JH; Kim DW; Schafhausen P; Matczak E; Leip E; Noonan K; Brümmendorf TH; Gambacorti-Passerini C
    Am J Hematol; 2016 Dec; 91(12):1206-1214. PubMed ID: 27531525
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
    Jabbour E; Kantarjian HM; Saglio G; Steegmann JL; Shah NP; Boqué C; Chuah C; Pavlovsky C; Mayer J; Cortes J; Baccarani M; Kim DW; Bradley-Garelik MB; Mohamed H; Wildgust M; Hochhaus A
    Blood; 2014 Jan; 123(4):494-500. PubMed ID: 24311723
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions.
    Schoenbeck KL; Flynn KE
    Curr Hematol Malig Rep; 2021 Dec; 16(6):491-499. PubMed ID: 34648119
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors.
    Schoenbeck KL; Atallah E; Lin L; Weinfurt KP; Cortes J; Deininger MWN; Kota V; Larson RA; Mauro MJ; Oehler VG; Pinilla-Ibarz J; Radich JP; Schiffer CA; Shah NP; Silver RT; Thompson JE; Flynn KE
    J Natl Cancer Inst; 2022 Jan; 114(1):160-164. PubMed ID: 34491344
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chronic Myeloid Leukemia Patient's Voice About the Experience of Treatment-Free Remission Failure: Results From the Italian Sub-Study of ENESTPath Exploring the Emotional Experience of Patients During Different Phases of a Clinical Trial.
    Borghi L; Galimberti S; Baratè C; Bonifacio M; Capochiani E; Cuneo A; Falzetti F; Iurlo A; Lunghi F; Minotto C; Orlandi EM; Rege-Cambrin G; Sica S; Supekar S; Haenig J; Vegni E
    Front Psychol; 2019; 10():329. PubMed ID: 30842749
    [No Abstract]   [Full Text] [Related]  

  • 60. Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study.
    Yu L; Wang H; Milijkovic D; Huang X; Jiang Q
    BMC Cancer; 2018 Aug; 18(1):782. PubMed ID: 30075760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.